Advertisement

Breast Cancer

, Volume 23, Issue 4, pp 540–545 | Cite as

Histological assessment of therapeutic response in breast cancer

  • Rie Horii
  • Futoshi Akiyama
Special Feature Current situation of pathology practice for breast cancers in Japan

Abstract

Histological assessment of the therapeutic response to neoadjuvant therapy gives us information regarding the efficacy of a given treatment in individual patients. Such information is useful for guiding selection of appropriate therapeutic strategies after surgery. In many studies of neoadjuvant chemotherapy (NAC) for breast cancer, both the histological therapeutic effect in the primary lesion and the lymph node metastatic status are significantly related to prognosis. The histological assessment of therapeutic response helps determine prognosis in breast cancer treated with NAC; however, methodological problems remain. There are many different histological criteria currently used to assess therapeutic response. Even when the same criteria are used, use of different methods for examination of surgical material can cause different results for the same patient case. When histological therapeutic effect is determined in daily clinical practice, pathologists have to describe the criteria used and their examination methods. Histological criteria for evaluation of therapeutic response and methods for examination of surgical materials after neoadjuvant therapy must be standardized in the near future.

Keywords

Breast cancer Pathology Neoadjuvant therapy Histological assessment of therapeutic response 

Notes

Conflict of interest

All authors declare that there are no conflicts of interest.

References

  1. 1.
    Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monographs. 2001;30:96–102.CrossRefPubMedGoogle Scholar
  2. 2.
    van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer Trial 10902. J Clin Oncol. 2001;19:4224–37.PubMedGoogle Scholar
  3. 3.
    Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenbeg MS, Robidoux A, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26:778–85.CrossRefPubMedGoogle Scholar
  4. 4.
    Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Moliterni A, Terenziani M, et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol. 1998;16:93–100.PubMedGoogle Scholar
  5. 5.
    Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006;24:2019–27.CrossRefPubMedGoogle Scholar
  6. 6.
    Symmans WF, Peintinger F, Rajan R, Kuerer H, Valeri V, Assad L, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25:4414–22.CrossRefPubMedGoogle Scholar
  7. 7.
    Penault-Llorca F, Abrial C, Raoelfils I, Cayre A, Mouret-Reynier MA, Leheurter M, et al. Comparison of the prognostic significance of Chevallier and Sataloff’s pathologic classifications after neoadjuvant chemotherapy of operable breast cancer. Hum Pathol. 2008;39:1221–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Sahoo S, Lester SC. Pathology of breast carcinomas after neoadjuvant chemotherapy: an overview with recommendations on specimen processing and reporting. Arch Pathol Lab Med. 2009;133:633–42.PubMedGoogle Scholar
  9. 9.
    Kurosumi M, Akashi-Tanaka S, Akiyama F, Komoike Y, Mukai H, Nakamura S, et al. Histological criteria for assessment of therapeutic response in breast cancer (2007 version). Breast Cancer. 2007;15:5–7.Google Scholar
  10. 10.
    Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 2002;20:1456–66.CrossRefPubMedGoogle Scholar
  11. 11.
    Von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;35(15):1796–804.CrossRefGoogle Scholar
  12. 12.
    Mazouni C, Peintinger F, Wan-Kau S, et al. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol. 2007;25(19):2650–5.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Breast Cancer Society 2013

Authors and Affiliations

  1. 1.Division of PathologyCancer Institute, Japanese Foundation for Cancer ResearchTokyoJapan

Personalised recommendations